Cargando…

Transparency and public accessibility of clinical trial information in Croatia: how it affects patient participation in clinical trials

INTRODUCTION: Despite increased visibility of clinical trials through international trial registries, patients often remain uninformed of their existence, especially if they do not have access to adequate information about clinical research, including the language of the information. The aim of this...

Descripción completa

Detalles Bibliográficos
Autores principales: Šolić, Ivana, Stipčić, Ana, Pavličević, Ivančica, Marušić, Ana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Croatian Society of Medical Biochemistry and Laboratory Medicine 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5493165/
https://www.ncbi.nlm.nih.gov/pubmed/28694716
http://dx.doi.org/10.11613/BM.2017.027
_version_ 1783247453117480960
author Šolić, Ivana
Stipčić, Ana
Pavličević, Ivančica
Marušić, Ana
author_facet Šolić, Ivana
Stipčić, Ana
Pavličević, Ivančica
Marušić, Ana
author_sort Šolić, Ivana
collection PubMed
description INTRODUCTION: Despite increased visibility of clinical trials through international trial registries, patients often remain uninformed of their existence, especially if they do not have access to adequate information about clinical research, including the language of the information. The aim of this study was to describe the context for transparency of clinical trials in Croatia in relation to countries in Central and Eastern Europe, and to assess how informed Croatian patients are about clinical trials and their accessibility. MATERIALS AND METHODS: We assessed the transparency of clinical trials from the data available in the public domain. We also conducted an anonymous survey on a convenience sample of 257 patients visiting two family medicine offices or an oncology department in south Croatia, and members of national patients’ associations. RESULTS: Despite legal provisions for transparency of clinical trials in Croatia, they are still not sufficiently visible in the public domain. Among countries from Central and Eastern Europe, Croatia has the fewest number of registered trials in the EU Clinical Trials Registry. 66% of the patients in the survey were aware of the existence of clinical trials but only 15% were informed about possibilities of participating in a trial. Although 58% of the respondents were willing to try new treatments, only 6% actually participated in a clinical trial. Only 2% of the respondents were aware of publicly available trial registries. CONCLUSIONS: Our study demonstrates that there is low transparency of clinical trials in Croatia, and that Croatian patients are not fully aware of clinical trials and the possibilities of participating in them, despite reported availability of Internet resources and good communication with their physicians. There is a need for active policy measures to increase the awareness of and access to clinical trials to patients in Croatia, particularly in their own language.
format Online
Article
Text
id pubmed-5493165
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Croatian Society of Medical Biochemistry and Laboratory Medicine
record_format MEDLINE/PubMed
spelling pubmed-54931652017-07-10 Transparency and public accessibility of clinical trial information in Croatia: how it affects patient participation in clinical trials Šolić, Ivana Stipčić, Ana Pavličević, Ivančica Marušić, Ana Biochem Med (Zagreb) Research Integrity Corner INTRODUCTION: Despite increased visibility of clinical trials through international trial registries, patients often remain uninformed of their existence, especially if they do not have access to adequate information about clinical research, including the language of the information. The aim of this study was to describe the context for transparency of clinical trials in Croatia in relation to countries in Central and Eastern Europe, and to assess how informed Croatian patients are about clinical trials and their accessibility. MATERIALS AND METHODS: We assessed the transparency of clinical trials from the data available in the public domain. We also conducted an anonymous survey on a convenience sample of 257 patients visiting two family medicine offices or an oncology department in south Croatia, and members of national patients’ associations. RESULTS: Despite legal provisions for transparency of clinical trials in Croatia, they are still not sufficiently visible in the public domain. Among countries from Central and Eastern Europe, Croatia has the fewest number of registered trials in the EU Clinical Trials Registry. 66% of the patients in the survey were aware of the existence of clinical trials but only 15% were informed about possibilities of participating in a trial. Although 58% of the respondents were willing to try new treatments, only 6% actually participated in a clinical trial. Only 2% of the respondents were aware of publicly available trial registries. CONCLUSIONS: Our study demonstrates that there is low transparency of clinical trials in Croatia, and that Croatian patients are not fully aware of clinical trials and the possibilities of participating in them, despite reported availability of Internet resources and good communication with their physicians. There is a need for active policy measures to increase the awareness of and access to clinical trials to patients in Croatia, particularly in their own language. Croatian Society of Medical Biochemistry and Laboratory Medicine 2017-06-15 2017-06-15 /pmc/articles/PMC5493165/ /pubmed/28694716 http://dx.doi.org/10.11613/BM.2017.027 Text en This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc-nd/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Integrity Corner
Šolić, Ivana
Stipčić, Ana
Pavličević, Ivančica
Marušić, Ana
Transparency and public accessibility of clinical trial information in Croatia: how it affects patient participation in clinical trials
title Transparency and public accessibility of clinical trial information in Croatia: how it affects patient participation in clinical trials
title_full Transparency and public accessibility of clinical trial information in Croatia: how it affects patient participation in clinical trials
title_fullStr Transparency and public accessibility of clinical trial information in Croatia: how it affects patient participation in clinical trials
title_full_unstemmed Transparency and public accessibility of clinical trial information in Croatia: how it affects patient participation in clinical trials
title_short Transparency and public accessibility of clinical trial information in Croatia: how it affects patient participation in clinical trials
title_sort transparency and public accessibility of clinical trial information in croatia: how it affects patient participation in clinical trials
topic Research Integrity Corner
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5493165/
https://www.ncbi.nlm.nih.gov/pubmed/28694716
http://dx.doi.org/10.11613/BM.2017.027
work_keys_str_mv AT solicivana transparencyandpublicaccessibilityofclinicaltrialinformationincroatiahowitaffectspatientparticipationinclinicaltrials
AT stipcicana transparencyandpublicaccessibilityofclinicaltrialinformationincroatiahowitaffectspatientparticipationinclinicaltrials
AT pavlicevicivancica transparencyandpublicaccessibilityofclinicaltrialinformationincroatiahowitaffectspatientparticipationinclinicaltrials
AT marusicana transparencyandpublicaccessibilityofclinicaltrialinformationincroatiahowitaffectspatientparticipationinclinicaltrials